gilead.com

Evaluation du site gilead.com

 Généré le 14 Décembre 2022 00:39

Vieilles statistiques? UPDATE !

Le score est de 56/100





Optimisation du contenu

Titre

Gilead Sciences, Inc.

Longueur : 21

Idéalement, votre titre devrait contenir entre 40 et 70 caractères (espaces compris). Utilisez cet outil gratuit pour calculer la longueur du texte.

Description

Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.

Longueur : 153

Génial, votre balise META description contient entre 90 et 160 caractères.

Mots-clefs

Très mauvais. Nous n'avons pas trouvé de balise META keywords sur votre page. Utilisez ce générateur gratuit de balises META en ligne pour créer des mots-clés.

Propriétés Open Graph

Bien, cette page profite des balises META Open Graph.

Propriété Contenu
title Gilead Sciences, Inc.
description Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
image https://wwwam10.gilead.com/-/media/gilead-corporate/images/og/gilead_logo.jpg

Niveaux de titre

H1 H2 H3 H4 H5 H6
1 7 4 3 1 0
  • [H1] World AIDS Day: Striving Together Toward Equity
  • [H2] Contact
  • [H2] Creating a Better Healthier World
  • [H2] Connecting Breast Cancer Education to Community: Equal Hope
  • [H2] Latinas Contra Cancer Empowers Patients to Advocate for Change
  • [H2] Tatiana Williams Leads the Way with the Transinclusive Group
  • [H2] Social
  • [H2] Headline
  • [H3] Advancing Global Health
  • [H3] Sustainability
  • [H3] Partnerships and Community
  • [H3] Recent Stories
  • [H4] Community
  • [H4] Community
  • [H4] Community
  • [H5] Recent News

Images

Nous avons trouvé 16 image(s) sur cette page Web.

Bien, la plupart ou la totalité de vos images possèdent un attribut alt

Ratio texte/HTML

Ratio : 40%

Idéal! le ratio de cette page texte/HTML est entre 25 et 70 pour cent.

Flash

Parfait, aucun contenu FLASH n'a été détecté sur cette page.

Iframe

Dommage, vous avez des Iframes sur vos pages Web, cela signifie que son contenu ne peut pas être indexé par les moteurs de recherche.

Réécriture d'URLs

Bien. Vos liens sont optimisés!

Tiret bas dans les URLs

Parfait! Aucuns soulignements détectés dans vos URLs.

Liens dans la page

Nous avons trouvé un total de 161 lien(s) dont 1 lien(s) vers des fichiers

Texte d'ancre Type Juice
Medicine Questions Externe Passing Juice
Report an Adverse Event Interne Passing Juice
Investors Interne Passing Juice
Contact Interne Passing Juice
Canada Externe Passing Juice
Mexico Interne Passing Juice
USA Interne Passing Juice
Argentina Interne Passing Juice
Brazil Interne Passing Juice
China Mainland Externe Passing Juice
Hong Kong Interne Passing Juice
India Interne Passing Juice
Japan Externe Passing Juice
Korea Externe Passing Juice
Singapore Interne Passing Juice
Taiwan Interne Passing Juice
Israel Externe Passing Juice
Saudi Arabia Interne Passing Juice
Türkiye Interne Passing Juice
United Arab Emirates Interne Passing Juice
South Africa Interne Passing Juice
Australia and New Zealand Interne Passing Juice
Austria Interne Passing Juice
Belgium and Luxembourg Externe Passing Juice
Czech Republic & Slovakia Interne Passing Juice
Denmark Interne Passing Juice
Finland Interne Passing Juice
France Externe Passing Juice
Germany Externe Passing Juice
Greece Interne Passing Juice
Iceland Interne Passing Juice
Ireland Interne Passing Juice
Italy Externe Passing Juice
Netherlands Interne Passing Juice
Norway Interne Passing Juice
Poland & The Baltics Interne Passing Juice
Portugal Interne Passing Juice
Romania Interne Passing Juice
Russia Interne Passing Juice
Spain Externe Passing Juice
Sweden Interne Passing Juice
Switzerland Interne Passing Juice
United Kingdom Externe Passing Juice
Mission and Core Values Interne Passing Juice
Partnerships and Community Interne Passing Juice
Inclusion and Diversity Interne Passing Juice
Corporate Giving Interne Passing Juice
Gilead Foundation Interne Passing Juice
Sustainability Interne Passing Juice
Advancing Global Health Interne Passing Juice
Medication Access Interne Passing Juice
Leadership Interne Passing Juice
How We Operate Interne Passing Juice
Ethics and Code of Conduct Interne Passing Juice
Therapeutic Areas Interne Passing Juice
Medicines Interne Passing Juice
Pipeline Interne Passing Juice
Research Interne Passing Juice
Clinical Trials Externe Passing Juice
Events Interne Passing Juice
Stories Interne Passing Juice
Newsroom Interne Passing Juice
Company Statements Interne Passing Juice
Annual Reports Interne Passing Juice
Careers at Gilead Interne Passing Juice
Our Culture Interne Passing Juice
Meet Our Employees Interne Passing Juice
Inclusion and Diversity in Hiring Interne Passing Juice
Compensation, Benefits and Wellbeing Interne Passing Juice
Our Global Footprint Interne Passing Juice
Early Career Opportunities Interne Passing Juice
Postdoctoral Fellowships Interne Passing Juice
Hiring Events Externe Passing Juice
Talent Community Sign-up Externe Passing Juice
Privacy Statements Interne Passing Juice
Terms Of Use Interne Passing Juice
Social Media Guidelines Interne Passing Juice
EU Data Disclosure Interne Passing Juice
Sitemap Interne Passing Juice
BACK TO MAIN MENU Interne Passing Juice
COMPASS Initiative Interne Passing Juice
HepConnect Interne Passing Juice
HIV Age Positively Interne Passing Juice
Lift Interne Passing Juice
RADIAN Interne Passing Juice
TRANScend Interne Passing Juice
What We Fund Interne Passing Juice
Funding Requests Interne Passing Juice
Zeroing In: Ending the HIV Epidemic Interne Passing Juice
Creating Possible Fund Interne Passing Juice
Our Business Is Sustainable Interne Passing Juice
Performance Interne Passing Juice
Reporting Interne Passing Juice
U.N. Global Compact Interne Passing Juice
U.N. Sustainable Development Goals Interne Passing Juice
COVID-19 Interne Passing Juice
HCV Elimination Interne Passing Juice
U.S. Patient Access Interne Passing Juice
Disaster Product Replacement Interne Passing Juice
Global Access Interne Passing Juice
Authorized Distributors Interne Passing Juice
ESG Goals Interne Passing Juice
Governance Interne Passing Juice
Transparency Interne Passing Juice
Policies Interne Passing Juice
Anti-Bribery and Anti-Corruption Policy Interne Passing Juice
Animal Use and Welfare Policy Interne Passing Juice
Disclosures Interne Passing Juice
Anti-Counterfeiting Interne Passing Juice
Consumer Product Safety Interne Passing Juice
Supplier Information Interne Passing Juice
Political Engagement Interne Passing Juice
Research Scholars Program Interne Passing Juice
Compassionate Use Interne Passing Juice
Investigator-Sponsored Research Interne Passing Juice
Press Releases Interne Passing Juice
Media Inquiries Interne Passing Juice
Gilead Receives Complete Response Letter from U.S. FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus Interne Passing Juice
Gilead Continues Efforts to Halt the Distribution of Counterfeit HIV Medications and Protect Patient Safety Interne Passing Juice
Veklury® (Remdesivir) Demonstrates Continued In Vitro Antiviral Activity Against Omicron Subvariants, Including BA.4 and BA.5 Interne Passing Juice
Sacituzumab Govitecan-Hziy Trodelvy Elevated to Category 1 Preferred Recommendation in Second-Line Metastatic Triple-Negative Breast Cancer Interne Passing Juice
Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir Interne Passing Juice
Gilead Statement on U.S. Supreme Court Overturning Roe v. Wade Interne Passing Juice
All Magrolimab Studies Re-Opening for Patient Enrollment in the U.S. Interne Passing Juice
Gilead Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleration of Prequalification Submission Interne Passing Juice
Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products Interne Passing Juice
Gilead to Expand Footprint in Oceanside Interne Passing Juice
Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities Interne Passing Juice
Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare Interne Passing Juice
Gilead Announces Actions to Remove Counterfeit HIV Medications from US Supply Chain Interne Passing Juice
Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia Interne Passing Juice
Veklury® (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression Interne Passing Juice
Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates Interne Passing Juice
Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant Interne Passing Juice
Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir Interne Passing Juice
Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union Interne Passing Juice
Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy®) in Second-Line and Later Metastatic Triple-Negative Breast Cancer Interne Passing Juice
Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees Interne Passing Juice
Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States Interne Passing Juice
Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis Interne Passing Juice
Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B) Interne Passing Juice
Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer Interne Passing Juice
Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19 Interne Passing Juice
Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Interne Passing Juice
Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Interne Passing Juice
Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services Interne Passing Juice
Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD Interne Passing Juice
Gilead Sciences Statement on Recent Events in Washington, D.C. Interne Passing Juice
Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP® Interne Passing Juice
Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines Interne Passing Juice
- Interne Passing Juice
- Interne Passing Juice
Year in Review 2021 Interne Passing Juice
Cookie Statement Interne Passing Juice
Partnership Request Interne Passing Juice
Gilead Sciences Again Named to Dow Jones Sustainability World Index Interne Passing Juice
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response Interne Passing Juice
- Externe Passing Juice
Stories@Gilead Interne Passing Juice
Investor Calls Interne Passing Juice
Modern Slavery Act Statement Interne Passing Juice

Mots-clefs

Nuage de mots-clefs

back      remdesivir      gilead      main      statement      menu      together      sciences      community      hiv     

Cohérence des mots-clefs

Mot-clef Contenu Titre Mots-clefs Description Niveaux de titre
gilead 37
back 16
main 16
menu 16
statement 16

Ergonomie

Url

Domaine : gilead.com

Longueur : 10

Favicon

Génial, votre site web dispose d'un favicon.

Imprimabilité

Aucun style CSS pour optimiser l'impression n'a pu être trouvé.

Langue

Bien. Votre langue est : en.

Dublin Core

Cette page ne profite pas des métadonnées Dublin Core.

Document

Doctype

HTML 5

Encodage

Parfait. Votre charset est UTF-8.

Validité W3C

Erreurs : 12

Avertissements : 15

E-mail confidentialité

Attention! Au moins une adresse e-mail a été trouvée en texte clair. Utilisez une protection anti-spam gratuite pour cacher vos e-mails aux spammeurs.

HTML obsolètes

Génial! Nous n'avons pas trouvé de balises HTML obsolètes dans votre code.

Astuces vitesse

Excellent, votre site n'utilise pas de tableaux imbriqués.
Mauvais, votre site web utilise des styles css inline.
Génial, votre site web contient peu de fichiers CSS.
Mauvais, votre site web contient trop de fichiers javascript (plus de 6).
Parfait : votre site tire parti de gzip.

Mobile

Optimisation mobile

Icône Apple
Méta tags viewport
Contenu FLASH

Optimisation

Sitemap XML

Manquant

Votre site web ne dispose pas d’une sitemap XML, ce qui peut poser problème.

La sitemap recense les URLs que les moteurs de recherche peuvent indexer, tout en proposant d’éventuelles informations supplémentaires (comme la date de dernière mise à jour, la fréquence des changements, ainsi que leur niveau d’importance). Ceci permet aux moteurs de recherche de parcourir le site de façon plus efficace.

Robots.txt

http://gilead.com/robots.txt

Votre site dispose d’un fichier robots.txt, ce qui est optimal.

Mesures d'audience

Manquant

Nous n'avons trouvé aucun outil d'analytics sur ce site.

Un outil de mesure d'audience vous permet d'analyser l’activité des visiteurs sur votre site. Vous devriez installer au moins un outil Analytics. Il est souvent utile d’en rajouter un second, afin de confirmer les résultats du premier.

PageSpeed Insights

Dispositif
Les catégories

Website Review

Website Review est un outil gratuit de référencement qui vous aidera à analyser vos pages web